{"id":70719,"date":"2026-05-12T09:49:37","date_gmt":"2026-05-12T09:49:37","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70719"},"modified":"2026-10-15T10:33:58","modified_gmt":"2026-10-15T10:33:58","slug":"follistatin-344","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ja\/product\/follistatin-344\/","title":{"rendered":"Follistatin 344"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">\u30af\u30a4\u30c3\u30af\u30a2\u30f3\u30b5\u30fc \u2014 \u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\u3068\u306f\uff1f<\/h3>\n<p style=\"margin: 0;\"><strong>Follistatin 344<\/strong> (FST-344) is a 344-amino-acid recombinant glycoprotein and the longer of the two principal splice isoforms of human follistatin. It is the canonical endogenous antagonist of myostatin (GDF-8) and activin, used in published studies investigating muscle hypertrophy, sarcopenia, muscular dystrophy preclinical models, and the activin\/myostatin signalling axis. Supplied in 1\u00a0mg lyophilized vials.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>MedsBase\u3067\u5f97\u3089\u308c\u308b\u3082\u306e\uff1a<\/strong> Pharmaceutical-grade lyophilized peptides &middot; HPLC &ge;99% purity (COA on request) &middot; Discreet protective packaging &middot; Worldwide peptide courier &middot; 1,400+ verified <a href=\"https:\/\/medsbase.com\/ja\/reviews\/\">\u30ab\u30b9\u30bf\u30de\u30fc\u30ec\u30d3\u30e5\u30fc<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 \u3059\u3079\u3066\u306e\u3054\u6ce8\u6587\u306f\u3001\u5f53\u5e97\u306e <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\"><strong>\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/strong><\/a> \u2014 \u4e07\u304c\u4e00\u300120\u55b6\u696d\u65e5\u4ee5\u5185\u306b\u5546\u54c1\u304c\u5c4a\u304b\u306a\u3044\u5834\u5408\u306f\u3001\u518d\u767a\u9001\u3044\u305f\u3057\u307e\u3059\u3002<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">\u4ed5\u69d8<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">\u8a73\u7d30<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS\u756a\u53f7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">80449-31-6\uff08\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u30bf\u30a4\u30d7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u7d44\u63db\u3048\u7cd6\u30bf\u30f3\u30d1\u30af\u8cea\uff08\u30d2\u30c8\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3\u306e344\u30a2\u30df\u30ce\u9178\u30b9\u30d7\u30e9\u30a4\u30b9\u30a2\u30a4\u30bd\u30d5\u30a9\u30fc\u30e0FST-344\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u7d0437\u2009kDa\uff08\u6210\u719f\u578b\u7cd6\u9396\u4ed8\u52a0\u4f53\uff1b\u7cd6\u9396\u4ed8\u52a0\u72b6\u614b\u306b\u5fdc\u3058\u3066SDS-PAGE\u3067\u89b3\u5bdf\u3055\u308c\u308b\u7bc4\u56f2\u306f\u7d0438\uff5e42\u2009kDa\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u69cb\u9020<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">N\u672b\u7aef\u30d8\u30d1\u30ea\u30f3\u7d50\u5408\u30c9\u30e1\u30a4\u30f3\u306b\u7d9a\u3044\u30663\u3064\u306e\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3\u30c9\u30e1\u30a4\u30f3\uff08FSD1\u3001FSD2\u3001FSD3\uff09\u304c\u5b58\u5728\u3057\u3001\u305d\u308c\u305e\u308cEGF\u69d8\u30b5\u30d6\u30c9\u30e1\u30a4\u30f3\u3068\u30ab\u30b6\u30fc\u30eb\u69d8\u30b5\u30d6\u30c9\u30e1\u30a4\u30f3\u3092\u542b\u3080\uff1b\u30b7\u30b9\u30c6\u30a4\u30f3\u30ea\u30c3\u30c1\u3067\u3001\u591a\u6570\u306e\u5206\u5b50\u5185\u30b8\u30b9\u30eb\u30d5\u30a3\u30c9\u7d50\u5408\u3092\u6709\u3059\u308b\u3002<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u5f62\u614b<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\uff08\u767d\u8272\uff5e\u5fae\u9ec4\u8272\uff09<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u7d14\u5ea6<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226595%\uff08HPLC\u691c\u8a3c\u6e08\u307f\u3001\u5206\u6790\u8a3c\u660e\u66f8\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u4fdd\u7ba1\u65b9\u6cd5<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u51cd\u7d50\u4e7e\u71e5\u54c1\uff1a\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\uff08\u51b7\u8535\u5eab\uff09\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u7ba1\u306f\u221220\u00b0C\u3067\u3059\u3002\u518d\u6eb6\u89e3\u5f8c\uff1a2\uff5e8\u00b0C\u3067\u7d0430\u65e5\u4ee5\u5185\u306b\u3054\u4f7f\u7528\u304f\u3060\u3055\u3044\u3002\u5149\u304b\u3089\u4fdd\u8b77\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u6eb6\u89e3\u6db2\u306e\u51cd\u7d50\u878d\u89e3\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044 \u2014 \u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\u306f\u7279\u306b\u51cd\u7d50\u878d\u89e3\u306b\u3088\u308b\u5909\u6027\u3092\u53d7\u3051\u3084\u3059\u3044\u305f\u3081\u3067\u3059\u3002<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u6eb6\u89e3\u6027<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u9759\u83cc\u6c34\uff08\u63a8\u5968\uff09\u307e\u305f\u306f\u77ed\u3044\u4f7f\u7528\u671f\u9593\u306e\u5834\u5408\u306f\u6ec5\u83cc\u6c34\u3092\u304a\u4f7f\u3044\u304f\u3060\u3055\u3044\u3002\u4f5c\u696d\u5e0c\u91c8\u6db2\u306e\u5438\u7740\u30ed\u30b9\u3092\u6700\u5c0f\u9650\u306b\u6291\u3048\u308b\u305f\u3081\u3001\u30ad\u30e3\u30ea\u30a2\u30bf\u30f3\u30d1\u30af\u8cea\uff08BSA\u30010.1%\uff09\u306e\u4efb\u610f\u6dfb\u52a0\u3092\u304a\u52e7\u3081\u3057\u307e\u3059\u3002<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\u3068\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h2>\n<p><strong>Follistatin 344<\/strong> (often abbreviated FST-344) is a recombinant 344-amino-acid glycoprotein and the longer of the two principal physiological splice isoforms of human follistatin \u2014 the other being FST-288, a shorter 288-amino-acid membrane-bound form. Endogenous follistatin was first isolated in 1987 from porcine ovarian follicular fluid by Esch et al. (PNAS) and Robertson et al. (Biochem Biophys Res Commun) as a factor that selectively inhibits follicle-stimulating hormone (FSH) secretion, which gave the protein its name. The mechanistic role \u2014 high-affinity binding and neutralisation of activin and myostatin \u2014 was characterised over the subsequent decade. FST-344 is a circulating, secreted isoform with a heparin-binding N-terminal domain followed by three cysteine-rich follistatin domains (FSD1, FSD2, FSD3) that together form the activin- and myostatin-binding surface. The recombinant 344-residue chain has a mature mass of approximately 37\u00a0kDa, with apparent molecular weight on SDS-PAGE varying between 38 and 42\u00a0kDa depending on the glycosylation state of the recombinant expression system. CAS number 80449-31-6. The protein is supplied as a high-purity lyophilized powder for reconstitution with bacteriostatic water. Follistatin is <strong>\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u305b\u3093<\/strong> by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. For related anabolic and growth-axis studies, see our <a href=\"https:\/\/medsbase.com\/ja\/igf-1-lr3\/\">IGF-1 LR3<\/a> \u88fd\u54c1\u30da\u30fc\u30b8\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2>\u4f5c\u7528\u6a5f\u5e8f \u2014 \u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u30fb\u30a2\u30af\u30c1\u30d3\u30f3\u7d4c\u8def\u62ee\u6297\u4f5c\u7528<\/h2>\n<p>What makes follistatin 344 mechanistically unique among muscle-studies proteins is its <strong>\u591a\u6a19\u7684\u7d50\u5408\u30d7\u30ed\u30d5\u30a1\u30a4\u30eb<\/strong> across the TGF-\u03b2 superfamily \u2014 each ligand-binding event contributing to the observed hypertrophic and growth-modulatory phenotype in published studies:<\/p>\n<ul>\n<li><strong>Myostatin\uff08GDF-8\uff09\u306e\u9694\u96e2 \u2014 \u7b4b\u80a5\u5927\u8ef8<\/strong> \u2014 Follistatin binds myostatin (also called GDF-8) with high affinity, sterically blocking its interaction with the activin type II receptor (ActRIIB). Myostatin is the canonical endogenous negative regulator of muscle growth: knockout mice develop dramatic muscle hypertrophy (the &#8220;double-muscling&#8221; phenotype), and naturally myostatin-deficient cattle breeds (Belgian Blue, Piedmontese) show the same effect. By neutralising myostatin, follistatin removes the brake on muscle protein synthesis, producing hypertrophy in study models. This is the most-cited mechanism in the muscle-literature.<\/li>\n<li><strong>Activin A\u304a\u3088\u3073B\u306e\u9694\u96e2 \u2014 \u751f\u6b96\u3001\u5375\u5de3\u3001\u4e0b\u5782\u4f53\u30b7\u30b0\u30ca\u30eb\u4f1d\u9054<\/strong> \u2014 Follistatin&#8217;s original characterised function was binding and neutralising activin, a related TGF-\u03b2 superfamily member that stimulates FSH secretion from the pituitary, drives ovarian follicle development, and acts as a regulator of many cell types. By binding activin A, B, and AB heterodimers, follistatin shifts the activin\/inhibin balance in study models and modulates downstream Smad2\/Smad3 signalling.<\/li>\n<li><strong>GDF-11\u304a\u3088\u3073\u3088\u308a\u5e83\u7bc4\u306aTGF-\u03b2\u30b9\u30fc\u30d1\u30fc\u30d5\u30a1\u30df\u30ea\u30fc\u306e\u8abf\u7bc0<\/strong> \u2014 Follistatin also binds GDF-11 (closely related to myostatin) with somewhat lower affinity, alongside other TGF-\u03b2 superfamily members. GDF-11 is increasingly studied in aging studies because its endogenous levels decline with age and its modulation is implicated in age-related cardiac and CNS phenotypes. Follistatin 344 is one of the principal tools for investigating this axis.<\/li>\n<\/ul>\n<p>The three follistatin domains (FSD1, FSD2, FSD3) each contribute to the binding profile: FSD1 contains the principal myostatin-binding surface, FSD2 the principal activin-binding surface, and FSD3 contributes both binding affinity and structural stability. The heparin-binding N-terminal domain distinguishes the splice variants \u2014 FST-288 binds heparan sulfate strongly and is largely membrane-anchored, while FST-344 (this isoform) circulates more freely. This distinction is mechanistically relevant in study models studying systemic vs local follistatin effects. <\/p>\n<h2>Published Evidence<\/h2>\n<p>Follistatin 344 is used in clinical contexts that investigate:<\/p>\n<ul>\n<li><strong>Muscle hypertrophy and protein synthesis studies<\/strong> \u2014 AAV-\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3\u907a\u4f1d\u5b50\u5c0e\u5165\u7814\u7a76\u3092\u542b\u3080\u30de\u30a6\u30b9\u304a\u3088\u3073\u30e9\u30c3\u30c8\u306e\u7b4b\u80a5\u5927\u30e2\u30c7\u30eb\uff08Kota et al., Sci Transl Med 2009\uff09\uff1b\u7b4b\u7dda\u7dad\u30bf\u30a4\u30d7\u5225\u6a2a\u65ad\u9762\u7a4d\u3001\u7b4b\u6e7f\u91cd\u91cf\u3001\u529b\u767a\u63ee\u306b\u95a2\u3059\u308b\u7814\u7a76<\/li>\n<li><strong>\u7b4b\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u306e\u524d\u81e8\u5e8a\u30e2\u30c7\u30eb<\/strong> \u2014 \u30c7\u30e5\u30b7\u30a7\u30f3\u30cc\u578b\u7b4b\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u306emdx\u30de\u30a6\u30b9\u30e2\u30c7\u30eb\uff1b\u6a5f\u80fd\u7684\u80fd\u529b\u3001\u7b4b\u7dda\u7dad\u518d\u751f\u3001\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30f3\u975e\u4f9d\u5b58\u7684\u306a\u7b4b\u4fdd\u5b58<\/li>\n<li><strong>\u30b5\u30eb\u30b3\u30da\u30cb\u30a2\u304a\u3088\u3073\u52a0\u9f62\u306b\u4f34\u3046\u7b4b\u55aa\u5931<\/strong> \u2014 aged-mouse muscle phenotypes, anabolic resistance, fibre-type-shift studies<\/li>\n<li><strong>Cancer cachexia studies<\/strong> \u2014 \u62c5\u764c\u30de\u30a6\u30b9\u306b\u304a\u3051\u308b\u60aa\u6db2\u8cea\u30e2\u30c7\u30eb\u3001\u4f53\u7d44\u6210\u306e\u4fdd\u6301\u3001\u9664\u8102\u80aa\u4f53\u91cd\/\u4f53\u8102\u80aa\u91cf\u6bd4<\/li>\n<li><strong>Reproductive endocrinology studies<\/strong> \u2014 FSH suppression, ovarian follicle development, granulosa-cell biology, pituitary-gonadal-axis studies<\/li>\n<li><strong>Activin pathway studies<\/strong> \u2014 Smad2\/Smad3 signalling, EMT in cancer models, fibrosis studies, hepatic regeneration<\/li>\n<li><strong>Aging and GDF-11 axis studies<\/strong> \u2014 cardiac and CNS aging phenotypes, parabiosis-related studies, GDF-11\/myostatin balance with aging<\/li>\n<li><strong>Comparative anabolic studies<\/strong> \u2014 \uff5e\u3068\u306e\u76f4\u63a5\u6bd4\u8f03 <a href=\"https:\/\/medsbase.com\/ja\/igf-1-lr3\/\">IGF-1 LR3<\/a> (parallel anabolic pathway via IGF-1 receptor) for combined or comparative hypertrophy studies.<\/li>\n<\/ul>\n<p>For broader context on where follistatin 344 fits within the anabolic and growth-axis studies landscape, see <a href=\"https:\/\/medsbase.com\/ja\/igf-1-lr3\/\">IGF-1 LR3<\/a> \u6a19\u6e96\u7684\u306aIGF\u8ef8\u6bd4\u8f03\u5bfe\u8c61\u3068\u3057\u3066\u3001, <a href=\"https:\/\/medsbase.com\/ja\/cjc-1295-with-dac\/\">CJC-1295 with DAC<\/a> for GHRH-axis growth studies, and <a href=\"https:\/\/medsbase.com\/ja\/sermorelin\/\">Sermorelin<\/a> for shorter-acting GHRH use. Browse the full <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\">\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/a> \u5316\u5408\u7269\u9078\u629e\u306e\u305f\u3081\u306b\u3002 <\/p>\n<h2>\u5229\u7528\u53ef\u80fd\u306a\u529b\u4fa1\u3068\u6fc3\u5ea6<\/h2>\n<p>MedsBase stocks Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack formats with full reconstitution guidance:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d0\u30a4\u30a2\u30eb\u529b\u4fa1<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u4ee3\u8868\u7684\u306a\u4f7f\u7528\u4f8b<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u30d1\u30c3\u30af\u30b5\u30a4\u30ba<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standard strength \u2014 muscle hypertrophy and activin\/myostatin axis studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u300120\u3001\u307e\u305f\u306f30\u30d0\u30a4\u30a2\u30eb<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Follistatin 344 is a 37\u00a0kDa recombinant glycoprotein supplied at \u226595% HPLC purity. The 1\u00a0mg vial format is the standard strength for in vivo and in vitro work \u2014 one vial reconstituted with 1.0\u00a0mL bacteriostatic water yields a 1\u00a0mg\/mL working concentration sufficient for many weeks of cell-culture protocols or several rodent-protocol injections. <\/p>\n<h2>Follistatin 344\u3068IGF-1 LR3\u306e\u6bd4\u8f03<\/h2>\n<p>Follistatin 344\u3068 <a href=\"https:\/\/medsbase.com\/ja\/igf-1-lr3\/\">IGF-1 LR3<\/a> are the two most-cited recombinant anabolic proteins in current hypertrophy studies. They act on entirely different pathways \u2014 follistatin by removing the myostatin brake on muscle growth, IGF-1 LR3 by directly stimulating the IGF-1 receptor and downstream Akt\/mTOR protein synthesis \u2014 which makes them mechanistically complementary in protocols. <\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">\u8a55\u4fa1\u9805\u76ee<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Follistatin 344<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">IGF-1 LR3<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30a2\u30df\u30ce\u9178\u6570<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">344\u30a2\u30df\u30ce\u9178\uff08\u7d44\u63db\u3048\u7cd6\u30bf\u30f3\u30d1\u30af\u8cea\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">83\u30a2\u30df\u30ce\u9178\uff08\u6539\u5909\u578bIGF-1\uff09<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u5206\u5b50\u91cf<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~37 kDa<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~9 kDa<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e3b\u306a\u4f5c\u7528\u6a5f\u5e8f<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30df\u30aa\u30b9\u30bf\u30c1\u30f3\uff0f\u30a2\u30af\u30c1\u30d3\u30f3\u9694\u96e2<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">IGF-1\u53d7\u5bb9\u4f53\u4f5c\u52d5 \u2192 Akt\uff0fmTOR<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u52b9\u679c\u30e2\u30fc\u30c9<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u8131\u6291\u5236\uff08\u6210\u9577\u30d6\u30ec\u30fc\u30ad\u306e\u89e3\u9664\uff09<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u76f4\u63a5\u7684\u306a\u540c\u5316\u523a\u6fc0<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u4e00\u822c\u7684\u306a\u7528\u91cf<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\uff5e100mcg\u3001\u90311\uff5e3\u56de<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">20\uff5e60mcg\u3001\u6bce\u65e5<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Strongest signal<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u5168\u7b4b\u80a5\u5927\u3001\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u30e2\u30c7\u30eb<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Local hypertrophy, regenerative anabolic studies<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u30b9\u30bf\u30c3\u30ad\u30f3\u30b0<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Commonly co-administered with IGF-1 LR3 in hypertrophy studies<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\u3068\u306e\u4f75\u7528\u304c\u4e00\u822c\u7684<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Because the two proteins act on fundamentally different anabolic axes \u2014 follistatin removes the myostatin brake while IGF-1 LR3 directly stimulates protein synthesis \u2014 combined administration is commonly used in study models exploring maximal hypertrophic response. For studies interested in the myostatin pathway specifically, follistatin 344 is the canonical first choice; for IGF\/Akt\/mTOR anabolic studies, IGF-1 LR3 is the canonical tool. <\/p>\n<h2>\u4fdd\u7ba1\u65b9\u6cd5\u3068\u518d\u6eb6\u89e3<\/h2>\n<p><strong>\u518d\u6eb6\u89e3\u524d\uff1a<\/strong> \u51cd\u7d50\u4e7e\u71e5\u30d0\u30a4\u30a2\u30eb\u306f\u3001\u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u3068\u3057\u3066\u3001\u5143\u306e\u5305\u88c5\u306e\u307e\u307e2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u672a\u958b\u5c01\u306e\u9577\u671f\u4fdd\u5b58\u306e\u5834\u5408\u306f\u3001-20\u00b0C\u3067\u51cd\u7d50\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u51cd\u7d50\u4e7e\u71e5\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\u306f\u3001\u51b7\u8535\u3067\u6700\u592712\u30f6\u6708\u9593\u3001-20\u00b0C\u3067\u6700\u592724\u30f6\u6708\u9593\u5b89\u5b9a\u3067\u3059\u304c\u3001\u5927\u578b\u306e\u7d44\u63db\u3048\u7cd6\u30bf\u30f3\u30d1\u30af\u8cea\u306f\u6642\u9593\u306e\u7d4c\u904e\u3068\u3068\u3082\u306b\u8131\u30a2\u30df\u30c9\u5316\u3084\u9178\u5316\u3092\u53d7\u3051\u3084\u3059\u3044\u305f\u3081\u3001\u5c0f\u578b\u5408\u6210\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u671f\u9593\u306f\u3084\u3084\u77ed\u304f\u306a\u308a\u307e\u3059\u3002\u51cd\u7d50\u4e7e\u71e5\u7c89\u672b\u306e\u51cd\u7d50\u878d\u89e3\u30b5\u30a4\u30af\u30eb\u306f\u907f\u3051\u3066\u304f\u3060\u3055\u3044\u3002 <strong>\u518d\u6eb6\u89e3\u624b\u9806\uff1a<\/strong> \u9759\u83cc\u6c34\u3092\u30da\u30d7\u30c1\u30c9\u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u306b\u6cbf\u3063\u3066\u6ce8\u5165\u3057\u307e\u3059\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\u3067\u304f\u3060\u3055\u3044\uff09\u30021 mg\u30d0\u30a4\u30a2\u30eb\u306e\u5834\u5408\u30011.0 mL\u306e\u9759\u83cc\u6c34\u30671 mg\/mL\u306e\u4f5c\u696d\u6fc3\u5ea6\u306b\u306a\u308a\u307e\u3059\u3002\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u307e\u3059\u2014\u2014 <strong>\u3057\u307e\u305b\u3093<\/strong> \u632f\u76ea\u3057\u2014\u20145\uff5e10\u5206\u9593\u7f6e\u3044\u3066\u5b8c\u5168\u306b\u6eb6\u89e3\u3055\u305b\u307e\u3059\u3002\u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\u306f\u5c0f\u578b\u30da\u30d7\u30c1\u30c9\u3088\u308a\u3082\u3086\u3063\u304f\u308a\u3068\u6eb6\u89e3\u3059\u308b\u305f\u3081\u3001\u6eb6\u89e3\u5de5\u7a0b\u3092\u6025\u304c\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u9069\u5207\u306b\u518d\u69cb\u6210\u3055\u308c\u305f\u6eb6\u6db2\u306f\u3001\u900f\u660e\u3067\u7121\u8272\u3001\u76ee\u306b\u898b\u3048\u308b\u7c92\u5b50\u304c\u306a\u3044\u306f\u305a\u3067\u3059\u3002100 mcg\/mL\u672a\u6e80\u306e\u4f5c\u696d\u5e0c\u91c8\u6db2\u3067\u306f\u3001\u30ad\u30e3\u30ea\u30a2\u30bf\u30f3\u30d1\u30af\u8cea\uff08BSA\u3092\u6700\u7d42\u6fc3\u5ea60.1%\u3067\u6dfb\u52a0\uff09\u3092\u52a0\u3048\u308b\u3053\u3068\u3067\u3001\u30d7\u30e9\u30b9\u30c1\u30c3\u30af\u3084\u30ac\u30e9\u30b9\u3078\u306e\u5438\u7740\u30ed\u30b9\u3092\u6700\u5c0f\u9650\u306b\u6291\u3048\u307e\u3059\u3002 <strong>\u5b8c\u5168\u306b\u518d\u6eb6\u89e3\u3057\u305f\u6eb6\u6db2\u306f\u3001\u7121\u8272\u900f\u660e\u3067\u3042\u308b\u5fc5\u8981\u304c\u3042\u308a\u307e\u3059\u3002<\/strong> 2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u3001\u6700\u9069\u306a\u5b89\u5b9a\u6027\u3092\u5f97\u308b\u305f\u3081\u306b30\u65e5\u4ee5\u5185\u306b\u4f7f\u7528\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u518d\u69cb\u6210\u3057\u305f\u6eb6\u6db2\u3092\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u2014\u2014\u7d44\u63db\u3048\u7cd6\u30bf\u30f3\u30d1\u30af\u8cea\u306f\u7279\u306b\u51cd\u7d50\u878d\u89e3\u5909\u6027\u306b\u654f\u611f\u3067\u3001\u51dd\u96c6\u3084\u6d3b\u6027\u4f4e\u4e0b\u3092\u5f15\u304d\u8d77\u3053\u3057\u307e\u3059\u3002\u6fc1\u308a\u3001\u6c88\u6bbf\u7269\u3001\u5909\u8272\u304c\u898b\u3089\u308c\u308b\u30d0\u30a4\u30a2\u30eb\u306f\u5ec3\u68c4\u3057\u3066\u304f\u3060\u3055\u3044\u3002 <\/p>\n<h2 id=\"faqs\">\u3088\u304f\u3042\u308b\u8cea\u554f<\/h2>\n<h3>What is Follistatin 344 used for in studies?<\/h3>\n<p>Follistatin 344 is used in studies investigating muscle hypertrophy, muscular dystrophy preclinical models, sarcopenia, cancer cachexia, the activin\/myostatin\/GDF-11 signalling axis, reproductive endocrinology (FSH suppression, ovarian follicle development), and aging-related phenotypes. It is the canonical tool for myostatin pathway antagonism. The pharmaceutical-grade follistatin 344 sold here is <strong>\u3057\u307e\u305b\u3093<\/strong> FDA-approved and is supplied strictly for clinical studies use only. <\/p>\n<h3>\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\u3068\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3315\u306e\u9055\u3044\u306f\u4f55\u3067\u3059\u304b\uff1f<\/h3>\n<p>FST-344\u306f\u30b7\u30b0\u30ca\u30eb\u30da\u30d7\u30c1\u30c9\u3092\u542b\u3080\u907a\u4f1d\u5b50\u7523\u7269\u306e344\u30a2\u30df\u30ce\u9178\u30a2\u30a4\u30bd\u30d5\u30a9\u30fc\u30e0\u3067\u3042\u308a\u3001FST-315\u306f\u5206\u6ccc\u6642\u306e\u30b7\u30b0\u30ca\u30eb\u30da\u30d7\u30c1\u30c9\u5207\u65ad\u5f8c\u306e\u540c\u3058\u30bf\u30f3\u30d1\u30af\u8cea\u3067\u3059\uff08\u3057\u305f\u304c\u3063\u3066FST-315\u306fFST-344\u306e\u6210\u719f\u5faa\u74b0\u578b\u3067\u3059\uff09\u3002\u4e21\u65b9\u306e\u547d\u540d\u6cd5\u306f\u6587\u732e\u306b\u767b\u5834\u3057\u3001\u540c\u3058\u751f\u7269\u5b66\u7684\u30a2\u30a4\u30bd\u30d5\u30a9\u30fc\u30e0\u3092\u6307\u3057\u307e\u3059\u3002\u3044\u305a\u308c\u3082\u3001\u3088\u308a\u77ed\u3044\u9078\u629e\u7684\u30b9\u30d7\u30e9\u30a4\u30b7\u30f3\u30b0\u30a2\u30a4\u30bd\u30d5\u30a9\u30fc\u30e0\u3067\u3001\u30d8\u30d1\u30e9\u30f3\u786b\u9178\u7d50\u5408\u304c\u5f37\u304f\u4e3b\u306b\u819c\u7d50\u5408\u5c40\u5728\u3092\u793a\u3059FST-288\u3068\u306f\u5927\u304d\u304f\u7570\u306a\u308a\u307e\u3059\u3002 <\/p>\n<h3>\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\u306fIGF-1 LR3\u3068\u3069\u306e\u3088\u3046\u306b\u7570\u306a\u308a\u307e\u3059\u304b\uff1f<\/h3>\n<p>Both are recombinant anabolic proteins used in muscle hypertrophy studies, but they target different pathways. Follistatin 344 is a 344-amino-acid glycoprotein that binds and sequesters myostatin and activin \u2014 it works by removing the endogenous brake on muscle growth. IGF-1 LR3 is an 83-amino-acid modified IGF-1 analog that directly agonises the IGF-1 receptor and activates Akt\/mTOR protein synthesis. The two are mechanistically complementary and frequently co-administered in studies. <\/p>\n<h3>What is the typical Follistatin 344 dose?<\/h3>\n<p>Published preclinical protocols typically use 10\u2013100\u00a0mcg per administration in rodent models, given 1\u20133 times weekly for 4\u201312 week cycles. Gene-delivery studies using AAV-follistatin produces tissue-localised concentrations that are difficult to compare directly to systemic-protein dosing. A 1\u00a0mg vial reconstituted with 1.0\u00a0mL bacteriostatic water yields 1\u00a0mg\/mL \u2014 0.01\u00a0mL equals 10\u00a0mcg, 0.1\u00a0mL equals 100\u00a0mcg. <\/p>\n<h3>Follistatin 344\u306fFDA\u627f\u8a8d\u3055\u308c\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>No. Follistatin 344 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. AAV-follistatin gene therapy has been investigated in clinical trials for muscular dystrophy (e.g., Becker muscular dystrophy, inclusion body myositis) but is not FDA-approved. <\/p>\n<h3>Follistatin 344\u306f\u3069\u306e\u3088\u3046\u306b\u4fdd\u7ba1\u3059\u308c\u3070\u3088\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>\u51cd\u7d50\u4e7e\u71e5\u54c1\u30d0\u30a4\u30a2\u30eb\uff1a\u77ed\u671f\u4f7f\u7528\u306e\u4f5c\u696d\u7528\u30b9\u30c8\u30c3\u30af\u306f2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3001\u672a\u958b\u5c01\u30d0\u30a4\u30a2\u30eb\u306e\u9577\u671f\u4fdd\u5b58\u306f-20\u00b0C\u3067\u51b7\u51cd\u4fdd\u5b58\u3057\u3066\u304f\u3060\u3055\u3044\u3002\u6eb6\u89e3\u6db2\uff1a2\uff5e8\u00b0C\u3067\u51b7\u8535\u4fdd\u5b58\u3057\u300130\u65e5\u4ee5\u5185\u306b\u3054\u4f7f\u7528\u304f\u3060\u3055\u3044\u3002\u6eb6\u89e3\u6db2\u306f\u51cd\u7d50\u3057\u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u7d44\u63db\u3048\u7cd6\u30bf\u30f3\u30d1\u30af\u8cea\u306f\u7279\u306b\u51cd\u7d50\u878d\u89e3\u306b\u3088\u308b\u5909\u6027\u306e\u5f71\u97ff\u3092\u53d7\u3051\u3084\u3059\u304f\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u5e38\u306b\u76f4\u5c04\u65e5\u5149\u3092\u907f\u3051\u3066\u4fdd\u7ba1\u3057\u3066\u304f\u3060\u3055\u3044\u3002100mcg\/mL\u672a\u6e80\u306e\u5e0c\u91c8\u6db2\u3092\u4f5c\u6210\u3059\u308b\u5834\u5408\u306f\u3001\u30ad\u30e3\u30ea\u30a2\u30bf\u30f3\u30d1\u30af\u8cea\uff080.1% BSA\uff09\u306e\u6dfb\u52a0\u3092\u63a8\u5968\u3057\u307e\u3059\u3002 <\/p>\n<h3>Follistatin 344\u306e\u6eb6\u89e3\u65b9\u6cd5\u3092\u6559\u3048\u3066\u304f\u3060\u3055\u3044\u3002<\/h3>\n<p>\u4e0a\u8a18\u306e\u6eb6\u89e3\u624b\u9806\u306b\u5f93\u3063\u3066\u304f\u3060\u3055\u3044\u3002\u9759\u83cc\u6c34\u3092\u30d0\u30a4\u30a2\u30eb\u306e\u5074\u58c1\u306b\u6cbf\u3063\u3066\u52a0\u3048\uff08\u51cd\u7d50\u4e7e\u71e5\u30b1\u30fc\u30ad\u306b\u76f4\u63a5\u304b\u3051\u306a\u3044\u3067\u304f\u3060\u3055\u3044\uff09\u3001\u9759\u304b\u306b\u65cb\u56de\u3055\u305b\u3001\u5b8c\u5168\u306b\u6eb6\u89e3\u3059\u308b\u307e\u30675\uff5e10\u5206\u9593\u5f85\u3061\u307e\u3059\u3002\u6fc0\u3057\u304f\u632f\u3089 <strong>\u3057\u307e\u305b\u3093<\/strong> \u306a\u3044\u3067\u304f\u3060\u3055\u3044\u3002\u6fc0\u3057\u3044\u652a\u62cc\u306f\u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\u3092\u5909\u6027\u3055\u305b\u3001\u51dd\u96c6\u3092\u5f15\u304d\u8d77\u3053\u3059\u53ef\u80fd\u6027\u304c\u3042\u308a\u307e\u3059\u3002\u6b63\u3057\u304f\u6eb6\u89e3\u3055\u308c\u305f\u6eb6\u6db2\u306f\u3001\u7121\u8272\u900f\u660e\u3067\u3059\u30021mg\u30d0\u30a4\u30a2\u30eb\u306b1.0mL\u306e\u6eb6\u89e3\u6db2\u3092\u52a0\u3048\u305f\u5834\u5408\u3001\u4f7f\u7528\u6fc3\u5ea6\u306f1mg\/mL\u3068\u306a\u308a\u307e\u3059\u3002 <\/p>\n<h3>\u7d14\u5ea6\u306e\u898f\u683c\u304c99%\u3067\u306f\u306a\u304f95%\u306a\u306e\u306f\u306a\u305c\u3067\u3059\u304b\uff1f<\/h3>\n<p>Recombinant glycoproteins like follistatin 344 cannot achieve the \u226599% HPLC purity standard typical of small synthetic peptides because of the inherent heterogeneity of glycosylation in any recombinant expression system \u2014 different glycoforms appear as related peaks on HPLC that are not impurities but isoforms of the target protein. \u226595% HPLC purity is the standard pharmaceutical-grade specification for follistatin 344 and similar recombinant glycoproteins. SDS-PAGE typically shows a single band with the expected 38\u201342\u00a0kDa apparent mass range. <\/p>\n<h3>MedsBase\u3067\u306f\u3069\u306e\u5bb9\u91cf\u306e\u30ec\u30bf\u30eb\u30c8\u30eb\u30c1\u30c9\u3092\u53d6\u308a\u63c3\u3048\u3066\u3044\u307e\u3059\u304b\uff1f<\/h3>\n<p>MedsBase carries Follistatin 344 in 1\u00a0mg lyophilized vials. The vial is available in 10-vial, 20-vial, or 30-vial pack sizes. All vials are supplied at \u226595% HPLC purity with a certificate of analysis available on request. <\/p>\n<h3>Can Follistatin 344 and IGF-1 LR3 be stacked in studies?<\/h3>\n<p>Yes. Follistatin 344 and IGF-1 LR3 act on fundamentally different anabolic axes (myostatin antagonism vs IGF-1 receptor agonism) and are frequently co-administered in study models exploring maximal hypertrophic response. The two are mechanistically complementary rather than redundant, and combined-protocol literature describes additive or synergistic effects on muscle fibre cross-sectional area. <\/p>\n<h3>Does Follistatin 344 cause side reported effects?<\/h3>\n<p>Published preclinical studies has documented tolerability at typical doses, with the main on-target effect being muscle hypertrophy. Off-target findings include modulation of FSH and ovarian function (because activin signalling is suppressed) and potential effects on hepatic regeneration and pituitary regulation due to follistatin&#8217;s role in broader TGF-\u03b2 superfamily signalling. Systemic follistatin-protein dosing has different exposure characteristics than tissue-localised AAV-gene-delivery approaches. <\/p>\n<h3>Follistatin 344\uff08\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3344\uff09\u306e\u534a\u6e1b\u671f\u306f\u3069\u306e\u304f\u3089\u3044\u3067\u3059\u304b\uff1f<\/h3>\n<p>In preclinical studies, recombinant follistatin 344 has a plasma half-life of approximately 1\u20133 hours following intravenous administration, reflecting its size (37\u00a0kDa, above the renal filtration cutoff) and binding to circulating ligands. Tissue half-life is considerably longer because follistatin remains bound to its captured myostatin and activin targets, sequestering them away from receptors. Gene-delivery approaches produce a far longer effective duration of action because tissue expression continues over weeks to months. <\/p>\n<h3>How long does Follistatin 344 take to show effects in preclinical studies?<\/h3>\n<p>\u30de\u30a6\u30b9\u304a\u3088\u3073\u30e9\u30c3\u30c8\u306e\u30bf\u30f3\u30d1\u30af\u8cea\u6ce8\u5c04\u30d7\u30ed\u30c8\u30b3\u30eb\u306b\u304a\u3051\u308b\u7b4b\u80a5\u5927\u52b9\u679c\u306f\u3001\u901a\u5e38\u3001\u90311\u56de\u6295\u4e0e\u30672\uff5e4\u9031\u9593\u5f8c\u306b\u7d71\u8a08\u7684\u306b\u6709\u610f\u3068\u306a\u308a\u30018\uff5e12\u9031\u9593\u3092\u901a\u3058\u3066\u84c4\u7a4d\u3057\u7d9a\u3051\u307e\u3059\u3002\u30a2\u30af\u30c1\u30d3\u30f3\/FSH\u8ef8\u3078\u306e\u751f\u6b96\u30a8\u30f3\u30c9\u30dd\u30a4\u30f3\u30c8\u3078\u306e\u5f71\u97ff\u306f\u3001\u6295\u4e0e\u5f8c\u6570\u65e5\u4ee5\u5185\u306b\u691c\u51fa\u53ef\u80fd\u3067\u3059\u3002\u907a\u4f1d\u5b50\u5c0e\u5165\uff08AAV-\u30d5\u30a9\u30ea\u30b9\u30bf\u30c1\u30f3\uff09\u30d7\u30ed\u30c8\u30b3\u30eb\u3067\u306f\u3001\u6ce8\u5c04\u5f8c4\uff5e6\u9031\u9593\u307e\u3067\u306b\u6e2c\u5b9a\u53ef\u80fd\u306a\u7b4b\u80a5\u5927\u304c\u8a8d\u3081\u3089\u308c\u3001\u6570\u30f6\u6708\u306b\u308f\u305f\u3063\u3066\u9032\u884c\u3057\u7d9a\u3051\u307e\u3059\u3002 <\/p>\n<h3>Follistatin 344\u3092\u56fd\u969b\u914d\u9001\u3067\u6ce8\u6587\u3067\u304d\u307e\u3059\u304b\uff1f<\/h3>\n<p>Yes. MedsBase ships Follistatin 344 worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our <a href=\"https:\/\/medsbase.com\/ja\/medsbase-re-shipment-assurance-policy\/\">\u518d\u767a\u9001\u4fdd\u8a3c\u30dd\u30ea\u30b7\u30fc<\/a>. <!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Peptides for Anabolic, Growth-Axis, and Muscle Studies<\/h2>\n<ul>\n<li><a href=\"\/ja\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Long-arginine recombinant IGF-1 analog \u2014 direct IGF-1R agonist for Akt\/mTOR studies<\/li>\n<li><a href=\"\/ja\/cjc-1295-with-dac\/\"><strong>CJC-1295 with DAC<\/strong><\/a> \u2014 Long-acting GHRH analog \u2014 growth hormone axis support<\/li>\n<li><a href=\"\/ja\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Shorter-acting GHRH(1-29) analog \u2014 natural GH-pulse support<\/li>\n<li><a href=\"\/ja\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 \u9078\u629e\u7684\u30b0\u30ec\u30ea\u30f3\u4f5c\u52d5\u85ac \u2014 \u30b3\u30eb\u30c1\u30be\u30fc\u30eb\uff0f\u30d7\u30ed\u30e9\u30af\u30c1\u30f3\u3092\u4f34\u308f\u306a\u3044\u30af\u30ea\u30fc\u30f3\u306aGH\u30d1\u30eb\u30b9<\/li>\n<li><a href=\"\/ja\/tb-500\/\"><strong>TB-500\uff08\u30b5\u30a4\u30e2\u30b7\u30f3\u30d9\u30fc\u30bf-4\uff09<\/strong><\/a> \u2014 Systemic healing fragment \u2014 muscle and cardiac recovery<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>\u53c2\u8003\u6587\u732e<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Explore anabolic and growth-axis peptides<\/strong><\/p>\n<p style=\"margin: 0;\">\u3059\u3079\u3066\u3092\u95b2\u89a7 <a href=\"https:\/\/medsbase.com\/ja\/peptides\/\"><strong>\u30da\u30d7\u30c1\u30c9\u30ab\u30bf\u30ed\u30b0<\/strong><\/a>, \u3001\u95a2\u9023\u5316\u5408\u7269\u3068\u3057\u3066 <a href=\"https:\/\/medsbase.com\/ja\/igf-1-lr3\/\">IGF-1 LR3<\/a> for direct IGF-receptor anabolic studies, <a href=\"https:\/\/medsbase.com\/ja\/cjc-1295-with-dac\/\">CJC-1295 with DAC<\/a> for long-acting GHRH use, and <a href=\"https:\/\/medsbase.com\/ja\/tb-500\/\">TB-500<\/a> for systemic muscle and tissue recovery.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 344\u30a2\u30df\u30ce\u9178\u7d44\u63db\u3048\u7cd6\u30bf\u30f3\u30d1\u30af\u8cea<br \/>\n\u2705 \u30df\u30aa\u30b9\u30bf\u30c1\u30f3\u30fb\u30a2\u30af\u30c1\u30d3\u30f3\u7d4c\u8def\u30a2\u30f3\u30bf\u30b4\u30cb\u30b9\u30c8<br \/>\n\u2705 Muscle hypertrophy compound<br \/>\n\u2705 \u7b4b\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u524d\u81e8\u5e8a\u30e2\u30c7\u30eb<br \/>\n\u2705 HPLC\u7d14\u5ea695%\u4ee5\u4e0a\u3001\u5206\u6790\u8a3c\u660e\u66f8\u306f\u3054\u8981\u671b\u306b\u5fdc\u3058\u3066\u63d0\u4f9b<\/p>\n<p><strong>Follistatin 344<\/strong> \u306f\u7d44\u63db\u3048\u30bf\u30f3\u30d1\u30af\u8cea\u3067\u3059\u3002<\/p>","protected":false},"featured_media":70949,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6276,5441],"class_list":["post-70719","product","type-product","status-publish","has-post-thumbnail","product_cat-peptides","product_tag-follistatin","product_tag-peptide","first","instock","shipping-taxable","purchasable","product-type-variable","has-default-attributes"],"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product\/70719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/comments?post=70719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media\/70949"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/media?parent=70719"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_brand?post=70719"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_cat?post=70719"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ja\/wp-json\/wp\/v2\/product_tag?post=70719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}